01.02.2024 | ASO Author Reflections
ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?
verfasst von:
Jun-Yi Wu, MD, PhD, Jia-Yi Wu, MD, Yang-Kai Fu, MD, Mao-Lin Yan, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2024
Einloggen, um Zugang zu erhalten
Excerpt
Conversion therapy for unresectable hepatocellular carcinoma (uHCC) with transcatheter arterial chemoembolization (TACE), lenvatinib plus anti-PD-1 antibodies (PD-1) (triple therapy) has a high rate of tumor response and shown the potential to achieve long-term survival.
1,2 Some studies have reported that salvage surgery (SR) is safe and improve the prognosis of uHCC after conversion therapy.
3,4 However, most of these studies tended to be single-arm trials and have small number of cases. The impact of SR in uHCC after conversion therapy remain unknown. Thus, we performed a retrospective analysis to compare the impact of SR and non-SR in uHCC after conversion therapy with triple therapy. …